Meeting
2022 ASCO Annual Meeting
Autologous CD7-targeted CAR T-cell therapy for refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma.
Authors
Liping Zhao
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China
Liping Zhao , Jing Pan , Kaiting Tang , Yue Tan , Biping Deng , Zhuojun Ling , Weiliang Song , Alex H. Chang , Xiaoming Feng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT04840875
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7035)
DOI
10.1200/JCO.2022.40.16_suppl.7035
Abstract #
7035
Poster Bd #
266
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Safety and early efficacy results of phase 1 study of affinity tuned and trackable AIC100 CAR T cells in ICAM-1 positive relapsed and/or refractory advanced poorly differentiated and anaplastic thyroid cancers.
First Author: Samer Ali Srour
Poster
2023 ASCO Annual Meeting
Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.
First Author: Shiqi Li
Poster
2023 ASCO Annual Meeting
Examining safety and durable disease remission in R/R B-ALL after autologous CD19-directed CAR T cells produced by novel PRIMCAR manufacture platform.
First Author: Zhi Yang
Poster
2023 ASCO Annual Meeting
Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma.
First Author: Xinfeng Chen